Early acute myeloblastic leukemia treatment for childhood myelodysplastic syndrome with t(3;5) (NPM/MLF1).
Myelodysplastic syndromes (MDS) in childhood are rare hematologic diseases. MDS with t(3;5) (NPM/MLF1) is an unusual subtype without a well-defined clinical and prognostic pattern. A poor outcome has been reported, suggesting that hematopoietic transplantation is the only treatment option. Here in we described a 2-year-old child diagnosed with the disease, without a suitable hematopoietic donor, treated early in the disease with chemotherapy. He is alive and well 4 years after the end of treatment. This unusual MDS needs further studies to better understand the disease.
Sevilla
Julián
J
Oncohematología pediátrica Hospital Niño Jesús, Madrid, Spain. jsevilla.hnjs@salud.madrid.org
Fernández-Plaza
Sandra
S
Lassaletta
Alvaro
A
González-Vicent
Marta
M
Contra
Trinidad
T
Madero
Luis
L
D015703:Antigens, CD / Q000097:blood; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002675:Child, Preschool; D002893:Chromosomes, Human, Pair 3; D002895:Chromosomes, Human, Pair 5; D003520:Cyclophosphamide / Q000627:therapeutic use; D003561:Cytarabine / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy / Q000235:genetics* / Q000276:immunology; D008297:Male; D008727:Methotrexate / Q000627:therapeutic use; D015514:Oncogene Proteins, Fusion / Q000235:genetics*; D011241:Prednisone / Q000627:therapeutic use; D013866:Thioguanine / Q000627:therapeutic use; D014178:Translocation, Genetic; D016896:Treatment Outcome; D014750:Vincristine / Q000627:therapeutic use
D015703:Antigens, CD; C120078:NPM-MLF1 protein, human; D015514:Oncogene Proteins, Fusion; D003561:Cytarabine; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D013866:Thioguanine; D011241:Prednisone; D008727:Methotrexate